9:15am-9:20am

陳竺，中國衛(wèi)生部部長

　

9:20am-9:25am

William Chin，哈佛大學(xué)醫(yī)學(xué)院執(zhí)行院長

　

9:25am-9:30am

　

9:30am-9:35am

LUC Montagnier   諾貝爾生理學(xué)或醫(yī)學(xué)獎獲得者（2008年），聯(lián)合國教科文組織世界艾滋病研究與防治基金會主席

　

9:35am-9:45am

簽約儀式

 

9:45am-10:15am

LUC Montagnier，諾貝爾生理學(xué)或醫(yī)學(xué)獎獲得者（2008年），聯(lián)合國教科文組織世界艾滋病研究與防治基金會主席

　

10:15am-10:45am

William Chin，哈佛大學(xué)醫(yī)學(xué)院執(zhí)行院長

 

11:00am-11:30am

Stephen Friend，美國Sage Bionetworks研究中心

 

11:30am-12:00am

Garry Neil，美國強(qiáng)生公司副總裁

 

分會 1  主席：萬昭奎，美國輝瑞 高級主任科學(xué)家；美中生物醫(yī)學(xué)協(xié)會（CABA）

共同創(chuàng)建人，前任會長（2009-2010）     

2:00pm-2:30pm

Michael R. McGurk，美國飛翰律師事務(wù)所 劍橋辦公室 管理合伙人

Identify and protect intellectual property in pharmaceutical process and formulation innovation

2:30pm-3:00pm

陳少羽，美國科文頓•柏靈律師事務(wù)所北京辦公室 中國藥品法律團(tuán)隊的總負(fù)責(zé)人

Regulatory and Legal Considerations for Pharmaceutical Companies to Succeed in the U.S. and China

3:00pm-3:30pm

張引，美國米.張.吳.律師事務(wù)所 所長、合伙人

IP/Legal Aspects of International Biopharma R&D Collaborations

3:50pm-4:20pm

Adam Powell ，美國 Payer+Provider公司 合伙人、總裁

Improving health in the 21st Century: An overview of key changes caused by the American and Chinese healthcare reforms

4:20pm-4:50pm

Wansheng Jerry Liu ，美國Fox Rothschild 律師事務(wù)所 專利律師

How Similar Is biosimilar? Introducing the newest draft Guidance on Biosimilar Product Development by the US FDA

4:50pm-5:20pm

Tong Zhang ，美國Fish & Richardson PC律師事務(wù)所 紐約辦公室 律師 

The "America Invents Act": What you need to know

分會 2 共同主席： Mingde Xia，美國強(qiáng)生制藥集團(tuán) (Johnson & Johnson) 國際科技合

作部資深總監(jiān)

共同主席:  Min Chen，美國諾華公司高級科學(xué)家

2:00pm-2:30pm

Zheng Jiang，美國華盛頓大學(xué)醫(yī)學(xué)院 副教授

Metabolic activation-based prediction of toxicity in drug development

2:30pm-3:00pm

Allen Reitz ，賓夕法尼亞州生物技術(shù)中心 藥物研究所 CEO

New Approaches for the Treatment of Amyotrophic Lateral Sclerosis

3:00pm-3:30pm

Jean Wang，美國默克公司 高級主任研究員

Drug Product Development Challenges and Opportunities: Integrated Approach of Novel Formulations Technology

3:50pm-4:20pm

Jong yuh Cherng，臺灣國立中正大學(xué)化生系 副教授

Enhancing and targeting gene delivery by influenza virus

4:20pm-4:50pm

Guiqiang Liang，美國 Novartis公司 高級研究員

Opportunity of PBPK Modeling and Simulation in Drug Discovery

4:50pm-5:20pm

Dai Weiguo，美國強(qiáng)生公司 藥物產(chǎn)品發(fā)展部 科學(xué)總監(jiān)

Room Temperature Stable Biological Products without cold chain--Progress, Challenges and Opportunities

5:20pm-5:50pm

Srinivas Rao， 美國NIH疫苗研究部實驗動物部

 

分會 3 共同主席： Brian Rudkin，法國里昂高等師范大學(xué) 分子與細(xì)胞生物實驗室主任; 華東師范大學(xué) 紫江學(xué)者

共同主席:  Cui Jisong，Hua Medicine公司副總裁

2:00pm-2:30pm

劉新垣，中國科學(xué)院院士，上海生命科學(xué)研究院，

上海生物化學(xué)與細(xì)胞生物學(xué)研究所

Cancer Targeting Gene-Viro-Therapy

2:30pm-3:00pm

Brian Rudkin，法國里昂高等師范大學(xué) 分子與細(xì)胞生物實驗室主任;華東師范大學(xué) 紫江學(xué)者

Peptide aptamers: precision tools for early development of novel therapeutic compounds.

3:00pm-3:30pm

Serge Pampfer，比利時瓦隆地區(qū)生物技術(shù)孵化器  董事長

Building a successful cell therapy industry

3:50pm-4:20pm

Yulia Sidorova，芬蘭赫爾辛基大學(xué) 生物技術(shù)研究所 博士后

SMALL MOLECULAR WEIGHT ARTEMIN MIMETIC FOR THE TREATMENT OF NEUROPATHIC PAIN

4:20pm-4:50pm

Bin Shi，美國默克公司 RNAi治療部 高級生物學(xué)家

Challenges and Opportunities in the Development of siRNA Lipid Nanoparticles

4:50pm-5:20pm

Meng Xia，中國Transgene公司總經(jīng)理

 

5:20pm-5:50pm

Raphael Anasthase，法國 BioTray公司國際業(yè)務(wù)經(jīng)理

生物制品的研發(fā)與制造的挑戰(zhàn)

分會 4  主席： David E. Golan, Professor and Dean for Graduate Education        and Global Education Programs, Harvard Medical School

2:00pm-3:30pm

William W. Chin ， Executive Dean for Research, Harvard Medical School

 

Lee M. Nadler， Professor and Dean for Clinical and Translational Research, Harvard Medical School

 

Stephen Friend, President，Sage Bionetworks, Former SVP of Merck and Head of Oncology

 

Winston Patrick Kuo,Director of Harvard Catalyst Laboratory for Innovative Translational Technologies, Harvard Medical School

 

Jiping Wang,Associate Director of Hepatobilliary Cancer Program, Division of Surgical Oncology at Brigham and Women’s Hospital, Harvard Medical School and the Gastrointestinal Cancer Treatment Center at Dana-Farber Cancer Institute

 

Vincent Lotteau， Co-Founder of the European Institute on Systems Biology and Medicine, France

 

4:00pm-5:30pm

共同主席：  Dr. Yonghao Gui, Vice President of Fudan University, Dean of Fudan University Shanghai Medical College

共同主席： Quoqiang Chen, Vice President of Jiaotong University, Dean of Jiaotong University Medical School

4:00pm-5:30pm

Xuetao Cao, Professor and President of

Chinese Academy of Medical Science

 

Yonghao Gui, Vice President of Fudan University, Dean of Fudan University Shanghai Medical College

 

Hongzhuan Chen，Professor and Vice Dean of Jiaotong University Medical School

 

Yizhun Zhu, Professor and Dean of Fudan University School of Pharmacy

 

 

 

共同主席： Stephen Friend, President, Sage Bionetworks, Former SVP of Merck and Head of Oncology

共同主席：Jason Gang Jin, CEO of ShanghaiBio Corporation, EVP of Shanghai Biochip

9:00am-10:30am

Jingwu Zang， Senior Vice President and Head of GSK R&D China

 

Bin Peng, Global Head, Oncology Tanslational Medicine China

 

 

Kerry Blanchard, Senior Vice President and Head, Eli Lilly China Drug Development, China

 

Bei Zhang, Vice President, and Head of Lilly R&D China

 

John Luk, Head of Oncology, Roche R&D China

 

Steve Yang, Vice President and Head of R&D, Asia and Emerging Markets, AstraZeneca

 

 

Nicholas C. Dracopoli,  Vice President and Head of Oncology Biomarkers, Janssen Research & Development, USA

 

Dayao Zhao,  Head of J&J R&D China

 

 

10:30am-11:00am

11:00am-12:30pm

 

主席：Sean Zhang,  Medical Director and liaison to BMS China R&D at Discovery, SAPA-GP Elect-President

Guoqing Cao, VP and Global Head of Discovery, Hengrui Pharmaceutical Global R&D

 

Peng  Wang, CSO of  Simcere Pharmaceutical

 

John V. Oyler, CEO of BeiGene

 

Yue Wang, PI of R&D, BeiGene

 

12:30pm-2:00 pm

主辦： Fenglin Life Science Park

主席： Sophia Qian, Managing Director, Fenglin Life Science Park office

2:00 pm-3:30 pm

共同主席：Wenru Song, Head of Regional Oncology Development/Takeda Shanghai Development Center &Millennium: Takeda Oncology Company, USA

共同主席：Mao Mao, Research Fellow, Pfizer Worldwide Research and Development, USA

David A Flockhart, Chair of Indiana Institute for Personalized Medicine, Chair of Cancer Genomics and Professor of Medicine, Medical Genetics and Pharmacology, Director of Clinical Pharmacology, Indiana University School of Medicine in Indianapolis, USA

 

Wenru Song, Head of Regional Oncology Development/Takeda Shanghai Development Center &Millennium‘Takeda Oncology Company, USA

 

Mao Mao , Research Fellow, Pfizer Worldwide Research and Development, USA

 

Huichuan Sun , Professor of Zhongshan Hospital Liver Cancer Institute, Fudan University

 

Yidong Chen, Professor, Department of Epidemiology and Biostatistics, The University of Texas Health Science Center at San Antonio

 

3:30 pm-4:00 pm

4:00pm – 5:30 pm

共同主席： Jason Gang Jin, CEO of Shanghai Bio Corporation

共同主席： Harry Yang, CBA

Kelly Hong, General Manager of Affymetrix China

 

Yingshuang Chai, National Sales Leader, Clinical, East China Sr.District Manager，Molecular Cell Biology, Applied Biosystems, Part of Life Technologies

 

Hong Xie, General Manager, Sequenom China

 

Jason Gang Jin, CEO of ShanghaiBio Corporation

 

Hongyue Sun, VP of Operation Technology Platform, COO of Wuxi Genomic Center, Wuxi AppTec

 

Peter Yan,  Technical Program/Project Manager at Frederick National Laboratory for Cancer Research, NCI/NIH, USA

 

分會5  主席：  Zhiliang Wu，賓大醫(yī)學(xué)院 應(yīng)用基因?qū)W中心 主任

2:00pm-2:30pm

Marcia Levenstein，美國輝瑞公司 副總裁

Challenges and Opportunities in Drug Development for Rare Diseases　

2:30pm-3:00pm

Zhiliang Wu，賓大醫(yī)學(xué)院 應(yīng)用基因?qū)W中心 主任

New Paradigm of Genomics Guided Clinical Trials to Develop Targeted Therapy: A Case Study with Attention Deficit and Hyperactivity

3:00pm-3:30pm

Emmanuelle VOISIN，法國Voisin公司 CEO

Regulation : clinical trials fields in Europe

3:50pm-4:20pm

Li Xing，美國輝瑞公司 高級主任研究員

Discovery of poten, selective and efficacious p38 MARK Inhibitor as clinical drug candidate

4:20pm-4:50pm

趙秀麗，首都醫(yī)科大學(xué)附屬北京同仁醫(yī)院臨床藥理基地主任、國家藥物機(jī)構(gòu)檢查員

 

4:50pm-5:20pm

Haibo Wu，中國醫(yī)藥生物協(xié)會理事，中國統(tǒng)籌法優(yōu)選法與經(jīng)濟(jì)數(shù)學(xué)研究會統(tǒng)籌學(xué)分會常務(wù)理事

腦血管病創(chuàng)新藥物的臨床試驗研究

分會6  主席：Cai Li，美國默克公司 體內(nèi)藥理部中國負(fù)責(zé)人  

9:00am-9:30am

德國勃林格殷格翰公司

 

9:30am-10:00am

Zhanglin Lin，清華大學(xué)化工系 工業(yè)酶國家工程實驗室 副主任，中國微生物學(xué)會酶工程專業(yè)委員會 副主任

Recombinant production of peptides in Escherichia coli using cleavable self-aggregating tag (cSAT)

10:00am-10:30am

Liqiang Derek Tou，美國Taketa-Millennium 公司 研究員

An innovative room temperature sterilization equipment for Chinese market

10:45am-11:15am

Lijun Wang，美國Merck公司全球采購部 高級科學(xué)家

A Cost-Effective Method to Remove Palladium from Pharmaceutical Intermediates and APIs

11:15am-11:45am

 

分會7主席：Zhihong Chen，美國Eisai公司 首席科學(xué)家

9:00am-9:30am

Zhiyong Qiu，美國曼康公司 抗腫瘤產(chǎn)品研發(fā)部 副主任, 腫瘤免疫治療首席科學(xué)家

Quest for durable disease control by induction of optimal effector T cells in cancer patients

9:30am-10:00am

Raman Rao，賽諾菲巴斯德公司外部研發(fā)部亞太區(qū)負(fù)責(zé)人

External Partnerships and Internal discovery for successful Vaccine Development

10:00am-10:30am

王義漢，美國Adiad公司  研發(fā)副總監(jiān)

Recent Advances in Targeted Therapy for Oncology

10:45am-11:15am

Laura Hong，美國Merck公司 高級科學(xué)家

Challenges and Solutions for Maintaining Quality and Potency of the Product in Vaccine Development

11:15am-11:45am

Cedric Y. Szpirer，比利時Delphi Genetics公司 共同創(chuàng)始人

Use of bacterial selection genes to get higher yields and to remove antibiotic resistance genes in bioproductions

11:45am-12:15am

Sanjay D. Khare，美國ImmunGene公司 CEO

Empowered cytokine fused-antibodies to overcome limitations of first and second generation therapeutic antibodies

分會7   主席：Zhiyong Qiu，美國曼康公司 抗腫瘤產(chǎn)品研發(fā)部 副主任, 腫瘤免疫治療

首席科學(xué)家  

2:00pm-2:30pm

Anna Cherouvrier Hansson，Head of Business Development Life Science, Invest in Skåne

Introducing cancer research excellence in Southern Sweden

Dan Mogren，Business Development Director, Lund Life Science Incubator

Ulrika Ringdahl，Chief Communication Officer

Lars-Erik Eriksson，Chief Executive Officer, Clinical Laser Thermia

2:30pm-3:00pm

Karolina Österlund，Manager Field Application Scientist EU and Asia, Gyros AB, Uppsala, Sweden

Automated Nanoliter Scaled Immunoassay Performed on a Compact Disc:  Maximizing productivity and efficiency in protein bioanalytics

3:00pm-3:30pm

Binhui Ni，Sanofi

Sanofi:A diversified global healthcare leader---Creating Value Through Partnership

3:50pm-4:20pm

William Cao，President, China Biotech Group Ltd

Patient-Specific Cancer Immunotherapy

4:20pm-4:50pm

Feng Li，健能隆醫(yī)藥技術(shù)（上海）有限公司  副總裁

Turning the global pharmaceutical industry challenges into development opportunities to grow China Biotech businesses – the case for Generon

分會 4 主席： David Wong，美國加州大學(xué)洛杉磯分校牙科學(xué)院副院長、

    牙科研究所主任

9:00am-9:30am

Carl A.K. Borrebaeck，瑞典Lund大學(xué) 副校長，免疫技術(shù)系教授、癌癥轉(zhuǎn)化研究戰(zhàn)略中心創(chuàng)新健康計劃負(fù)責(zé)人

Molecular portraits associated with improved prognosis and

diagnosis of cancer

9:30am-10:00am

David Wong，美國加州大學(xué)洛杉磯分校牙科學(xué)院副院長、牙科研究所主任

Saliva: The Emerging Diagnostic Frontier

10:00am-10:30am

Davide Bedognetti，美國國立衛(wèi)生研究院臨床中心傳染病及免疫基因?qū)W部 主任助理、研究員

Biomarkers of immunoresponsiveness in cancer immunotherapy: hypothesis-driven and discovery-driven translational approaches

10:45am-11:15am

John Gu，美國新尚制藥公司 董事總經(jīng)理；美國國家癌癥研究院 兼職教授

 

11:15am-11:45am

1. President, CEO and co-founder, AltraBio;      2. CTO

ALTRABIO – INTEGRATIVE ANALYSIS OF LIFE SCIENCE DATA

11:45am-12:15am

Yuxun Wang（或S3）美國Metamark Genetics公司 研發(fā)副總監(jiān)

Integrate oncogenomics based anti-cancer drug target and biomarker

2:00pm-2:30pm

Achim Göpferich，德國雷根斯堡大學(xué) 藥物化學(xué)系主任

Nanoparticle Interactions with Cell Surface Receptors: New Keys for Old locks

2:30pm-3:00pm

Shoufeng Li，美國 Novartis公司 技術(shù)項目總監(jiān)

Recent advances in Pharmaceutics, Biopharmaceutics and Physiology Pharmaceutics

3:00pm-3:30pm

Michael F. Haller，美國Anaphore公司 戰(zhàn)略合作副總裁 

Differentiating Biosimilars through Drug Delivery

3:50pm-4:20pm

Jerry Zhang，美國Shire公司  高級研發(fā)經(jīng)理

Lipid Based Therapeutcis Nanoparticles

 

4:20pm-4:50pm

Steven Sun， 美國GeneWiz公司 總裁

 

2:00pm-2:30pm

Bai Chunxue，復(fù)旦大學(xué)附屬中山醫(yī)院呼吸科主任，上海呼吸病研究所主任

呼吸病患者的霧化吸入治療

2:30pm-3:00pm

Song Yuanlin，復(fù)旦大學(xué)附屬中山醫(yī)院呼吸科副主任，上海呼吸病研究所副主任

霧化吸入治療技術(shù)的進(jìn)展

 

3:00pm-3:30pm

 

 

3:50pm-4:20pm

 

 

1:30pm-1:40pm

上海對外科學(xué)技術(shù)交流中心領(lǐng)導(dǎo)致辭

 

1:40pm-2:10pm

董樹沛 上海市科學(xué)技術(shù)委員會生物醫(yī)藥處 副處長  

上海生物醫(yī)藥產(chǎn)業(yè)規(guī)劃與布局

2:10pm-2:40pm

張清 上海市食品藥品監(jiān)督管理局 藥品注冊處 副處長

上海市藥品注冊管理的政策解讀

2:40pm-3:10pm

徐國雄/李永忠/姜遠(yuǎn)英 上海醫(yī)藥集團(tuán)股份有限公司（副）總裁

新形勢下的醫(yī)藥產(chǎn)業(yè)發(fā)展

3:10pm-3:30pm

茶歇

 

3:30pm-4:10pm

沈競康 中科院上海藥物研究所研究員、博導(dǎo)、副所長

新形勢下的醫(yī)藥產(chǎn)業(yè)發(fā)展的機(jī)遇和挑戰(zhàn)

4:10pm-4:50pm

寧光  瑞金醫(yī)院副院長、內(nèi)分泌代謝科主任醫(yī)師

 

4:50pm-5:30pm

毛振民 交通大學(xué)藥學(xué)院教授

 

5:30pm-5:40pm

Q&A

 

6:00pm-7:00pm

招待晚宴

 

1:30pm-1:40pm

上海市科學(xué)技術(shù)委員會國際合作處領(lǐng)導(dǎo)致辭

 

1:40pm-2:10pm

王紅強(qiáng)，聯(lián)合利華大中華及東北亞區(qū)開放創(chuàng)新總監(jiān) 

聯(lián)合利華開放創(chuàng)新模式和生物技術(shù)領(lǐng)域的機(jī)遇

2:10pm-2:40pm

李林 聯(lián)合利華研究科學(xué)家

中長多肽及多肽藥物的高效制備技術(shù)

2:40pm-3:10pm

林旭 教授，中科院上海生命科學(xué)研究院營養(yǎng)科學(xué)研究所人類營養(yǎng)與疾病研究組組長

營養(yǎng)、遺傳變異與慢性代謝性疾病的人群研究

3:10pm-3:30pm

茶歇

 

3:30pm-4:00pm

劉保延 教授，中國針灸學(xué)會會長

 

4:00pm-4:30pm

劉承宜 教授，華南師范大學(xué)激光運動醫(yī)學(xué)實驗室主任

鼻腔內(nèi)低強(qiáng)度激光照射治療：臨床、基礎(chǔ)與應(yīng)用

4:30pm-5:00pm

東紅升 副研究員 上海市針灸經(jīng)絡(luò)研究所

針灸對糖尿病及并發(fā)癥的防治

5:00pm-5:30pm

Q&A

 

6:00pm-7:00pm

招待晚宴

 

● 標(biāo)準(zhǔn)套票

2400

會議資料，會議期間午餐，茶歇，晚宴, 贈送2張學(xué)生票。

● 團(tuán)體預(yù)定(5人以上)

2200

● 學(xué)生套票

1200

會議資料，會議期間午餐，茶歇